It tests for the presence or absence of ribonucleic acid (RNA) of Dengue (Type 1, 2 4) in serum or plasma from patients suspected of dengue viral infection.
First diagnostic centre to open in Mohali on August 31
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
The aim is to create new genomics solutions that could combat cancer and advance market access
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Price band in the range of Rs 933 to Rs 954
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
New Centre of Excellence brings advanced robotic platforms and multidisciplinary expertise under one roof to expand access to precision-led minimally invasive surgery
The move comes as demand rises for wider access to glaucoma screening and more flexible clinical workflows
The company reported consolidated revenue of Rs. 172.9 crore and EBITDA of Rs 25.9 crore in FY26
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
